Our Quality Management System (QMS) ensures that our quality system complies with FDA, EU and NMPA GMP requirement regarding material & supplier management, manufacturing management, data integrity, Good Documentation Practice (GDP) management, etc.
Our GMP facilities, equipment and personnel are strictly governed, monitored, and documented, to ensure that we can provide the best support to our clients covering all stages from development to commercial production.
Our carefully constructed core QMS governing structure consists of Quality Manual, Quality Policy, SOPs, Records, Forms, Protocols and Reports etc.
The Quality Manual is the highest-level document in Porton Advanced’s quality system, and any document shall not confilct with or be inconsistent with it. In case of any conflict, Quality Manual shall prevail unless otherwise stated. The Quality Policy describes the management strategy for different aspects of the quality system on the basis of Quality Manual. All Standard Operating and Management Procedures, Quality Specifications, Process Procedures or Job Descriptions are included in the documents that guide operations. Finally, Records, Protocols, Forms and Reports are the cornerstone of our quality system and are used to demonstrate that the quality system is in good operation.
Based on risk and science, the QMS regulates all of our operations, should be applied as appropriate to all projects and products at all stages.
Through years of operating as a CDMO, we have established a robust quality management system, with collective experiences in numerous key areas:
Our technology transfer activities include both technology and knowledge transfer of the product, manufacturing process or analytical methods throughout R&D and manufacturing stages.
The methods can be transferred between different manufacturing sites, as well as from clients to Porton Advanced.
We have established robust Technology Transfer procedure, based on planned and controlled transfer activities, which enable us to obtain products and analytical methods that meet clients’ requirements.
Our robust procurement process clearly defines the procurement of materials and related services required for development and manufacturing operation activities. This ensures that the purchased materials or services are of high quality, are traceable, and that suppliers can provide reliable and accurate input and value-added services.
Our import and export processes ensure that our import and export activities are compliant, smooth, and ensure the timely delivery of special goods, including microorganisms, human tissues, biological products, blood and its products, and biological materials of animal resource.
The established procedure also defines the documents required for customs inspection and related processes.
Our registration team have many years of global regulatory experience, such as with ICH, FDA and EU registrations. We also have established eCTD templates for IND and BLA registration.
We are able to provide:
©2023 Porton Advanced Solution Ltd. All Rights Reserved.
Porton Advanced Solutions is a subsidiary of Porton Pharma Solutions Ltd.
The repeatability study of selected samples at certain dilution levels showed great repeatability with a CV value of less than 10%.
Case study
Assays
Case Study
mRNA purity –AUC effectively distinguishes the different components in an mRNA sample, such as truncated mRNA (Peak 1), monomeric mRNA (Peak 2), long-chain mRNA, and mRNA aggregates (Peak 3& 4).
Figure 8
Lentivirus titer produced in two suspension cell production system:
A. Viral titer from a leading commercial packaging system. B. Viral titer from Porton Advanced’s PTLV-SMART packaging system.
Figure 4
T cell transduction with lentivirus produced using our HEK293T system. T cells are infected with lentivirus at different MOI. CAR-T cell percentages were measured by FACS.
Figure 20
Figure 7
Figure 5
Figure 6
An AAV variant from our library screening showed that the virus was able to package a 6.1kb genome.
Figure 19
AAV variants enriched in different tissues during library screening. AAV libraries were prepared and injected into the hosts. After two weeks, tissues were harvested and viral genomes were isolated for PacBio sequencing. Viral genomes were clustered against different tissues.
Figure 18
Separation of empty and full rAAV by anion chromatography. A: AEX result of rAAV5; B: AEX result of rAAV9
Figure 3
CAR expression with escalated MOI using PTLV-SMART platform. Activated T cells transduced with escalated MOI, and FACS employed to demonstrate CAR expression post-7 days culture in G-Rex.
Figure 1
Time course of CAR transduction rates of CD3 T cells and cell viability during manufacturing in two cases. T-cells transduced with lentivirus analyzed by flow cytometry to detect CAR-positive or Protein L-positive cell ratio. T-cells expressed CAR stably in the period of CAR-T cell growth with high cell viability.
Figure 2